• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Seroprevalence of bactericidal anti-meningococcal antibodies in Cantabria 10 months following a vaccination campaign].

作者信息

González de Aledo Linos A, García Merino J

机构信息

Consejería de Sanidad, Consumo y Bienestar Social del Gobierno de Cantabria.

出版信息

Rev Esp Salud Publica. 1998 Jul-Aug;72(4):365-74.

PMID:9810841
Abstract

BACKGROUND

The Self Governing Region of Cantabria within the state of Spain has a population of 541,885, of which 107,787 individuals are aged from 18 months to 19 years. A vaccination campaign against meningitis was conducted in this Region in February and March, 1997. It was directed at children from the age of 18 months up to 19 years old, and included all municipal areas, achieving a coverage of more than 95%. In the following 12 months the efficacy achieved by the vaccination was 95.68% for all age groups. To help decide on the need for re-vaccination, a study of the prevalence in serum of bactericide antibodies in the vaccinated population was carried out.

METHODS

In December 1997 blood samples from 414 vaccinated children were analysed, obtained at random in opportunist sampling in First-Aid Centres and Public Hospitals within this Region, as well as from children in public kindergartens run by the General Board of Social Well-Being in Cantabria. The number of bactericide antibodies was analysed in the National Centre for Microbiology, and the level of "vaccination effect" was set at a dilution of 1/8.

RESULTS

The following percentages of titres > or = 1/8 were obtained (the age groups of school pupils are shown in brackets): 0% (18-24 months old), 4% (1.5-4 years old), 7.1% (1.5 to 6 years old), 51.3% (6 to 12 years old). Due to the fact that the definition of the "vaccine effect" was artificially set at a dilution of 1/8, while other studies set it at a dilution of 1/4, in 287 serum samples with a result of < 1/8 the bactericide assay was repeated with a dilution of 1/4, with the result that 286 (99.6%) were negative. I.e., the final result does not vary if we set the cut-off point at 1/4 instead of 1/8. No significant differences were found due to whether or not the samples came from children in municipalities where there had been cases of meningitis C.

CONCLUSIONS

Bactericide activity is very low in those children aged less than 4-6 years old, and is less than has been published, although it is greater above this age. This contrasts with the excellent clinical-epidemiological results, as there was no case amongst the least serologically "protected" population, in spite of the fact that meningococcus C remains in circulation in Cantabria, within the population that was not targeted by the campaign.

摘要

相似文献

1
[Seroprevalence of bactericidal anti-meningococcal antibodies in Cantabria 10 months following a vaccination campaign].
Rev Esp Salud Publica. 1998 Jul-Aug;72(4):365-74.
2
[An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].[1997年多哥萨瓦内地区的脑膜炎球菌性脑膜炎疫情:研究与控制策略]
Sante. 1997 Nov-Dec;7(6):384-90.
3
[Evaluation of the vaccination campaign in Cantabria 2 years of epidemiological evolution].
Rev Esp Salud Publica. 2000 Jul-Aug;74(4):405-11.
4
[Effectiveness and duration of the immunity of the vaccine against serogroup A+C meningococcus].
Rev Esp Salud Publica. 2000 Jul-Aug;74(4):425-31.
5
[Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].[马德里社区脑膜炎球菌病的演变。A+C 型抗脑膜炎球菌疫苗的有效性]
Rev Esp Salud Publica. 2000 Jul-Aug;74(4):397-403.
6
[Evaluation of the effectiveness of targeted vaccination with the meningococcal polysaccharide A and C vaccine in one location in the Czech Republic].[在捷克共和国一个地区评估A群和C群脑膜炎球菌多糖疫苗的靶向接种效果]
Epidemiol Mikrobiol Imunol. 1995 Mar;44(1):9-14.
7
Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.B型脑膜炎球菌疫苗:新药。唯一针对某些B群脑膜炎球菌的疫苗。
Prescrire Int. 2008 Jun;17(95):95-7.
8
[Bactericidal activity against Neisseria meningitidis serogroup C in the vaccinated and non-vaccinated population of Andlucía].[针对安达卢西亚接种疫苗和未接种疫苗人群中脑膜炎奈瑟菌C群的杀菌活性]
Rev Esp Salud Publica. 1998 Sep-Oct;72(5):407-10.
9
[Levels of bactericidal antibodies against meningococcus C after vaccination in 2- to 6-year-old children in Andalusia].[安达卢西亚2至6岁儿童接种疫苗后抗C群脑膜炎球菌杀菌抗体水平]
Rev Esp Salud Publica. 2000 Jul-Aug;74(4):433-44.
10
Meningococcal C vaccines: the Canadian experience.脑膜炎球菌C疫苗:加拿大的经验
Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S280-4.

引用本文的文献

1
Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.在对儿童和青少年实施大规模疫苗接种计划24个月后,西班牙加泰罗尼亚地区C群脑膜炎球菌病发病率急剧下降。
J Epidemiol Community Health. 2001 Apr;55(4):283-7. doi: 10.1136/jech.55.4.283.